# US 2019/0290594 A1 · Mangiferin encapsulated gold nanoparticles, fabrication methods and cancer therapeutic methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0290594 A1
- Document ID: US20190290594A1
- Status: Published application
- Kind: A1
- Application number: 16/339,304
- Filed: 2017-10-03
- Published: 2019-09-26
- Earliest claimed: 2016-10-04
- Assignees: The Curators of the University of Missouri
- Applicants: The Curators of the University of Missouri
- Inventors: Kattesh Katti; Cathy Cutler; Menka Khoobchandani; Kavita Katti
- Web page: https://patentgrep.com/patent/US20190290594A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5115: {Inorganic compounds}
- A61K 9/5192: {Processes}
- A61K 51/0491: {Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers}
- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61P 35/00: Antineoplastic agents
- B22F 1/054: Nanosized particles
- B22F 1/0545: Dispersions or suspensions of nanosized particles
- B22F 1/102: Metallic powder coated with organic material
- B22F 9/24: starting from liquid metal compounds, e.g. solutions
- A61K 2121/00: Preparations for use in therapy
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B22F: WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER (making alloys by powder metallurgy C22C); APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A method for forming encapsulated gold nanoparticles mixes mangiferin into a liquid medium to form a reducing agent solution. Gold salts are mixed into the reducing agent solution. Reaction of the gold salts is permitted, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible gold nanoparticles coated with mangiferin. The gold salts can consist of AuCl4, or can consist of radioactive gold salts. A cancer therapy method injects a solution of mangiferin encapsulated gold nanoparticles directly into a solid tumor. A solution consisting of an aqueous or alcoholic medium and mangiferin encapsulated gold nanoparticles is provided. The mangiferin encapsulated gold nanoparticles can have core sizes of ˜5-20 nm and total sizes of ˜20-120 nm.

## Claims

### Claim 1

A method for forming encapsulated gold nanoparticles, the method comprising:
mixing mangiferin into a liquid medium to form a reducing agent solution;
mixing gold salts into the reducing agent solution;
permitting reaction of the gold salts, in the absence of any other reducing agent, to form a nanoparticle solution of stabilized, biocompatible gold nanoparticles coated with mangiferin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the liquid medium consists of distilled and/or de-ionized water.

### Claim 3 (depends on 1)

The method of claim 1, wherein the liquid medium consists of an alcoholic medium or a mixture of water and alcohol.

### Claim 4 (depends on 1)

The method of claim 1, wherein the gold salts consist of AuCl4.

### Claim 5 (depends on 1)

The method of claim 1, wherein the concentration of mangiferin in the reducing agent solution is in the range of 1.6-3.3 mM.

### Claim 6 (depends on 5)

The method of claim 5, wherein the concentration of gold salt is 1.7-3.4 mM.

### Claim 7 (depends on 6)

The method of claim 6, wherein said permitting reaction is conducted at an agent solution temperature of 80° C.-100° C.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the gold salts comprise radioactive gold salts.

### Claim 11 (depends on 10)

The method of claim 10, further comprising preliminary steps of preparing radioactive gold foil and dissolving the radioactive gold foil intoaqua regia and drying the liquid to produce radioactive gold istope in powdered form (Au-198), drying the 198Au powder, and dissolving the dried 198Au powder into the liquid medium, and mixing in NaAuCl4 to form the radioactive gold salts in the liquid medium.

### Claim 12 (depends on 11)

The method of claim 11, wherein preparing the radioactive gold foil comprises irradiating natural gold foil with a neutron flux.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 14)

The method of claim 14, wherein the mass ratio of 198Au to NaAuCl4 is selected to set an activity level.

### Claim 16 (depends on 11)

A method of therapy, comprising intratumorally directly injecting the nanoparticle solution formed according to claim 11 into a solid tumor.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method of therapy, comprising intratumorally directly injecting the nanoparticle solution formed according to claim 1 into a solid tumor.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The cancer therapy method of claim 19, wherein the tumor comprises a human prostate cancer tumor.

### Claim 22 (depends on 20)

The cancer therapy method of claim 20, wherein the mangiferin encapsulated gold nanoparticles comprise 198Au nanoparticles having core sizes of ˜5-50 nm.

### Claim 23 (depends on 22)

The cancer therapy method of claim 22, wherein a mass of 198Au is selected to set an activity level.

### Claim 24

(canceled)

### Claim 25

A solution consisting of an aqueous or alcoholic medium and mangiferin encapsulated gold nanoparticles.

### Claim 26 (depends on 25)

The solution of claim 25, wherein the mangiferin encapsulated gold nanoparticles comprises core sizes of ˜5-50 nm.

### Claim 27

A cancer therapy method, comprising obtaining a solution of mangiferin encapsulated gold nanoparticles, and introducing the solution into a human or animal for treating a solid, liquid, localized and metastatic tumors.

### Claim 28 (depends on 27)

The method of claim 27, wherein the mangiferin encapsulated gold nanoparticles are functionalized to have an affinity for cancer cells.
